121 related articles for article (PubMed ID: 21157026)
1. Long-term effects of galantamine treatment on brain functional activities as measured by PET in Alzheimer's disease patients.
Keller C; Kadir A; Forsberg A; Porras O; Nordberg A
J Alzheimers Dis; 2011; 24(1):109-23. PubMed ID: 21157026
[TBL] [Abstract][Full Text] [Related]
2. PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD.
Kadir A; Darreh-Shori T; Almkvist O; Wall A; Grut M; Strandberg B; Ringheim A; B Eriksson ; Blomquist G; Långström B; Nordberg A
Neurobiol Aging; 2008 Aug; 29(8):1204-17. PubMed ID: 17379359
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine.
Darreh-Shori T; Kadir A; Almkvist O; Grut M; Wall A; Blomquist G; Eriksson B; Långström B; Nordberg A
Neurobiol Aging; 2008 Feb; 29(2):168-84. PubMed ID: 17196712
[TBL] [Abstract][Full Text] [Related]
4. Functional connectivity increase in the default-mode network of patients with Alzheimer's disease after long-term treatment with Galantamine.
Blautzik J; Keeser D; Paolini M; Kirsch V; Berman A; Coates U; Reiser M; Teipel SJ; Meindl T
Eur Neuropsychopharmacol; 2016 Mar; 26(3):602-13. PubMed ID: 26796681
[TBL] [Abstract][Full Text] [Related]
5. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
Kadir A; Andreasen N; Almkvist O; Wall A; Forsberg A; Engler H; Hagman G; Lärksäter M; Winblad B; Zetterberg H; Blennow K; Långström B; Nordberg A
Ann Neurol; 2008 May; 63(5):621-31. PubMed ID: 18300284
[TBL] [Abstract][Full Text] [Related]
6. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
7. rCBF and cognitive impairment changes assessed by SPECT and ADAS-cog in late-onset Alzheimer's disease after 18 months of treatment with the cholinesterase inhibitors donepezil or galantamine.
Shirayama Y; Takahashi M; Oda Y; Yoshino K; Sato K; Okubo T; Iyo M
Brain Imaging Behav; 2019 Feb; 13(1):75-86. PubMed ID: 29247294
[TBL] [Abstract][Full Text] [Related]
8. Galantamine-induced improvements in cognitive function are not related to alterations in alpha(4)beta (2) nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18F]fluoro-A-85380 PET.
Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Saunder T; Young K; Smith CL; Welch J; Woodward M; Wesnes KA; Savage G; Rowe CC
Psychopharmacology (Berl); 2009 Jan; 202(1-3):79-91. PubMed ID: 18949462
[TBL] [Abstract][Full Text] [Related]
9. Metabolic patterns associated with the clinical response to galantamine therapy: a fludeoxyglucose f 18 positron emission tomographic study.
Mega MS; Dinov ID; Porter V; Chow G; Reback E; Davoodi P; O'Connor SM; Carter MF; Amezcua H; Cummings JL
Arch Neurol; 2005 May; 62(5):721-8. PubMed ID: 15883258
[TBL] [Abstract][Full Text] [Related]
10. The short-term effect of acetylcholinesterase inhibitor on the regional cerebral blood flow of Alzheimer's disease.
Cho H; Kwon JH; Seo HJ; Kim JS
Arch Gerontol Geriatr; 2010; 50(2):222-6. PubMed ID: 19398134
[TBL] [Abstract][Full Text] [Related]
11. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
[TBL] [Abstract][Full Text] [Related]
12. Cessation versus continuation of galantamine treatment after 12 months of therapy in patients with Alzheimer's disease: a randomized, double blind, placebo controlled withdrawal trial.
Scarpini E; Bruno G; Zappalà G; Adami M; Richarz U; Gaudig M; Jacobs A; Schäuble B
J Alzheimers Dis; 2011; 26(2):211-20. PubMed ID: 21606568
[TBL] [Abstract][Full Text] [Related]
13. Predicting the neural effect of switching from donepezil to galantamine based on single-photon emission computed tomography findings in patients with Alzheimer's disease.
Oka M; Nakaaki S; Negi A; Miyata J; Nakagawa A; Hirono N; Mimura M
Psychogeriatrics; 2016 Mar; 16(2):121-34. PubMed ID: 26114924
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial.
Pirttilä T; Wilcock G; Truyen L; Damaraju CV
Eur J Neurol; 2004 Nov; 11(11):734-41. PubMed ID: 15525294
[TBL] [Abstract][Full Text] [Related]
15. Galantamine Response Associates with Agitation and the Prefrontal Cortex in Patients with Alzheimer's Disease.
Nakayama S; Suda A; Nakanishi A; Motoi Y; Hattori N
J Alzheimers Dis; 2017; 57(1):267-273. PubMed ID: 28222509
[TBL] [Abstract][Full Text] [Related]
16. Cortical oxygen supply during postural hypotension is further decreased in Alzheimer's disease, but unrelated to cholinesterase-inhibitor use.
van Beek AH; Sijbesma JC; Jansen RW; Rikkert MG; Claassen JA
J Alzheimers Dis; 2010; 21(2):519-26. PubMed ID: 20555135
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the regional cerebral blood flow changes during long-term donepezil therapy in patients with Alzheimer's disease using 3DSRT.
Kimura N; Kumamoto T; Masuda T; Hanaoka T; Okazaki T; Arakawa R
J Neuroimaging; 2012 Jul; 22(3):299-304. PubMed ID: 21699607
[TBL] [Abstract][Full Text] [Related]
18. The clinical efficacy and safety of galantamine in the treatment of Alzheimer's disease.
Dengiz AN; Kershaw P
CNS Spectr; 2004 May; 9(5):377-92. PubMed ID: 15115951
[TBL] [Abstract][Full Text] [Related]
19. Decreased activation along the dorsal visual pathway after a 3-month treatment with galantamine in mild Alzheimer disease: a functional magnetic resonance imaging study.
Bokde AL; Karmann M; Teipel SJ; Born C; Lieb M; Reiser MF; Möller HJ; Hampel H
J Clin Psychopharmacol; 2009 Apr; 29(2):147-56. PubMed ID: 19512976
[TBL] [Abstract][Full Text] [Related]
20. Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine.
Bullock R; Erkinjuntti T; Lilienfeld S;
Dement Geriatr Cogn Disord; 2004; 17(1-2):29-34. PubMed ID: 14560062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
